Initiated U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC); initial results are expected in the first half of 2024 Initiated U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) and dosed the first patient; initial results... Read More